Your browser doesn't support javascript.
loading
Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy.
Chueh, Chen-Han; Tsai, Yi-Wen; Chen, Zi-Rong; Shiu, Ming-Neng; Wen, Yu-Wen; Chiang, Nai-Jung.
Afiliação
  • Chueh CH; Institute of Health and Welfare Policy, National Yang Ming Chiao Tung University, 112304, Taipei, Taiwan.
  • Tsai YW; Institute of Health and Welfare Policy, National Yang Ming Chiao Tung University, 112304, Taipei, Taiwan. ywtsai@nycu.edu.tw.
  • Chen ZR; Institute of Health and Welfare Policy, National Yang Ming Chiao Tung University, 112304, Taipei, Taiwan.
  • Shiu MN; Institute of Health and Welfare Policy, National Yang Ming Chiao Tung University, 112304, Taipei, Taiwan.
  • Wen YW; Department of Pharmacy, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Chiang NJ; Clinical Informatics and Medical Statistics Research Center, Chang Gung University, Taoyuan, Taiwan.
Pharmacoeconomics ; 41(3): 307-319, 2023 03.
Article em En | MEDLINE | ID: mdl-36575331
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Colangiocarcinoma / Análise de Custo-Efetividade Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Colangiocarcinoma / Análise de Custo-Efetividade Idioma: En Ano de publicação: 2023 Tipo de documento: Article